Dr. Sneha Kumar, Charles River’s Strategic Commercial Lead of Logica, explores the extent of what AI can do in the lab and how drug discovery happens if the technology is integrated at every step. The urgency of a new approach The numbers tell a story… Read More
Adityo Prakash, CEO of Verseon, introduces a new mathematical approach to computing molecular interactions. The objective of small-molecule drug discovery is to find binders to target proteins involved in disease processes. However, the discovery and development of novel small-molecule therapeutics remains one of the most resource-intensive endeavors… Read More
A naturally occurring molecule identified by Stanford Medicine researchers appears similar to semaglutide — also known as Ozempic — in suppressing appetite and reducing body weight. Notably, testing in animals also showed that it worked without some of Ozempic’s side effects such as nausea, constipation and significant loss of muscle… Read More
A new eBook is now available from Malvern Panalytical: ‘Faster, more accurate and deeper insight: How to make the switch to label-free interaction analysis.’ Label-free interaction analysis takes discovery to a new level. It removes inaccuracies and inefficiencies, but it also uncovers a new layer of insight… Read More
Label-free interaction analysis takes discovery to a new level. It removes inaccuracies and inefficiencies, but it also uncovers a new layer of insight into the kinetic activity and binding specificity of a greater range of analytes. GCI technology brings you closer to your analytes, allowing you to see interactions in… Read More
UK researchers at the Francis Crick Institute, Imperial College London and AstraZeneca will advance the discovery of new ‘molecular glues’ to treat a range of different diseases, thanks to a £11.2 million combined investment. The investment includes a Prosperity Partnership grant from the Engineering and Physical… Read More
University of Queensland researchers have pioneered a new chemical process to manufacture molecules that are the building blocks for lifesaving medicines, vaccines and energy storage materials. Professor Matt Trau from UQ’s Australian Institute for Bioengineering and Nanotechnology (AIBN) has been awarded an ARC Laureate Fellowship worth $2.9 million to further… Read More
Since the turn of the century, when the term “personalised medicine” was first coined, the use of molecular diagnostic (or biomarker) testing in clinical trials has continued to grow in terms of complexity and importance. These tests have undergone a period of rapid development and growth in the last decade, with the implementation… Read More
Albany Molecular Research (AMRI), provider of advanced contract research, development and manufacturing solutions, has been included in America’s Best Employers 2021 list, published by Forbes. AMRI was included in the Drugs and Biotechnology industry category of the ranking. Its 3,100 employees provide scientific solutions across the R&D and manufacturing continuum… Read More
